Entrada Therapeutics Inc (TRDA)
19.04
-0.92
(-4.61%)
USD |
NASDAQ |
Nov 14, 16:00
19.04
0.00 (0.00%)
After-Hours: 20:00
Entrada Therapeutics Research and Development Expense (Quarterly): 31.26M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 31.26M |
| June 30, 2024 | 32.04M |
| March 31, 2024 | 28.61M |
| December 31, 2023 | 28.29M |
| September 30, 2023 | 22.19M |
| June 30, 2023 | 26.30M |
| March 31, 2023 | 23.10M |
| December 31, 2022 | 15.68M |
| September 30, 2022 | 18.96M |
| Date | Value |
|---|---|
| June 30, 2022 | 16.25M |
| March 31, 2022 | 15.72M |
| December 31, 2021 | 12.36M |
| September 30, 2021 | 10.51M |
| June 30, 2021 | 6.829M |
| March 31, 2021 | 6.223M |
| December 31, 2020 | 6.656M |
| September 30, 2020 | 5.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.70M
Minimum
Sep 2020
32.04M
Maximum
Jun 2024
18.04M
Average
16.25M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Fulcrum Therapeutics Inc | 17.26M |
| Catalyst Pharmaceuticals Inc | 3.284M |
| Vertex Pharmaceuticals Inc | 875.90M |
| Assembly Biosciences Inc | 16.26M |
| Sarepta Therapeutics Inc | 224.48M |